PACE-CME

No definite difference for primary endpoint but proven safety with ARNI in MI patients

No definite difference for primary endpoint but proven safety with ARNI in MI patients
RestartResume
5' education - May 15, 2021 - Prof. Marc Pfeffer, MD, PhD
  • Overview

    ACC 2021 A short summary of the PARADISE-MI trial with sacubitril/valsartan compared to ramipril in MI patients is provided by prof. Pfeffer.

  • Educational information

    This video was recorded during the virtual congress of the ACC.21.

  • Faculty

    Dr. Marc Alan Pfeffer is a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH) and the Victor J. Dzau professor of medicine at Harvard Medical School, Boston, MA, USA.

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

    Read our summary of this trial

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free